INTERACTION OF THE HUMORAL AGONIST DURING THE PLATELETS ACTIVATION IN PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA

Cover Page

Abstract


Objective: The aim of the study was to determine the effect of the standard drug therapy of 95 patients with chronic cerebral ischemia (CCI) on the functional status of platelets as possible participants of microcirculation of the brain. Methods: Platelets were isolated from peripheral blood by centrifugation and examined at 24 hours after initiation of standard medical therapy including aspirin (100 mg). The cells were stimulated in vitro using adenosine diphosphate (ADP), epinephrine, platelet activating factor (PAF) and serotonin in an effective concentration (EC50) inducing in healthy individuals platelet aggregation in the range of 50±5%. A study of platelet aggregation was carried out on aggregometer Chrono-Log (USA). Results: Research included 82 patients with CCI 1–2 Stage — 76 patients taking antiplatelet and antihypertensive drugs before hospitalization (main group), 6 — did not receive these drugs during 7 days prior to hospitalization (comparison group). After start conservative treatment, only ADP induced platelet aggregation, which was similar (p >0.05) with values in healthy individuals. The pharmacological inhibition of the functional activity of platelets other investigated agonists reproduced hyporesponsiveness of platelets. Against this background, in 34 (44.7%) patients at 24 hours after initiation of therapy occurred potentiation effects of PAF and epinephrine in the test in vitro; whereas the summation of the effects of serotonin and epinephrine on platelets was detected in 12 (15.8%) patients. The basis of this phenomenon may be strengthening effect of ADP secreted from dense-granules, additional stimulation by Gi-protein signaling system by epinephrine and Gq-protein by the action of PAF and serotonin. Conclusion: Response to the combined action of platelet agonists may be predictor of the risk of thrombogenesis at CCI.

 


E. F. Barinov

M. Gorky Donetsk National Medical University, Donetsk, Ukraine

Author for correspondence.
Email: barinov.ef@gmail.com

Ukraine

октор медицинских наук, профессор, заведующий кафедрой гистологии, цитологии и
эмбриологии Донецкого национального медицинского университета им. М. Горького
Адрес: 83003, Украина, Донецк, пр-т Ильича, д. 16, тел.: +38 (062) 344-42-61

S. Mamedalieva

M. Gorky Donetsk National Medical University, Donetsk, Ukraine

Email: sevdamar@mail.ru

Ukraine

ассистент кафедры неврологии и медицинской генетики Донецкого национального
медицинского университета им. М. Горького
Адрес: 83003, Украина, Донецк, пр-т Ильича, д. 16, тел.: +38 (062) 295-62-89

T. A. Tverdokhleb

M. Gorky Donetsk National Medical University, Donetsk, Ukraine

Email: ivt-08@mail.ru

Ukraine

аспирант кафедры гистологии, цитологии и эмбриологии Донецкого
национального медицинского университета им. М. Горького
Адрес: 83003, Украина, Донецк, пр-т Ильича, д. 16, тел.: +38 (062) 344-42-56

  1. Tanahashi N. Antiplatelet therapy for secondary prevention of cerebral infarction. Nihon. Rinsho. 2014; 72 (7): 1270–1275.
  2. Lukasik M., Dworacki G., Michalak S., Kufel–Grabowska J., Watala C., Kozubski W. Chronic hyper-reactivity of platelets resulting in enhanced monocyte recruitment in patients after ischaemic stroke. Platelets. 2012; 23 (2): 132–142.
  3. Yano Y., Hoshide S., Etoh T., Tamaki N., Yokota N., Kario С. Synergistic effect of chronic kidney disease and high circulatory nor-epinephrine level on stroke risk in Japanese hypertensive patients. Atherosclerosis. 2011; 219 (1): 273–279.
  4. Clauss R. Disorders of consciousness and pharmaceuticals that act on oxygen based amino acid and monoamine neurotransmitter pathways of the brain. Curr. Pharm. Des. 2014; 20 (26): 4140–4153.
  5. Karakulova Yu.V., Kaigorodova N.B., Batueva E.A. Activation of humoral and serotonin influenced endogenous neurotrophin therapy for diabetic peripheral neuropathy. Meditsina i zdravookhranenie = Medicine and health care. 2013;3:13–17.
  6. Roth G.A., Gillespie C.W., Mokdad A.A., Shen D.D., Fleming D.W., Stergachis A., Murray C.J., Mokdad A.H. Aspirin use and knowledge in the community: a population and health facility based survey for measuring local health system performance. BMC. Cardiovasc. Disord. 2014; 7 (14): 16.
  7. Conrad M.F., Boulom V., Mukhopadhyay S., Garg A., Patel V.I., Cambria R.P. Progression of asymptomatic carotid stenosis despite optimal medical therapy. J. Vasc. Surg. 2013; 58 (1): 128–135.
  8. Richard S., Toussaint-Hacquard M., Fay R., Lacour J.C., Ducrocq X., Lecompte T. Laboratory effect on platelet activity within 24 h of the first 300 mg oral dose of aspirin given in hospital during the acute phase of ischemic cerebral events. Cerebrovasc. Dis. 2012; 33 (6): 574–578.
  9. Arnan M.K., Burke G.L., Bushnell C. Secondary prevention of stroke in the elderly: focus on drug therapy. Drugs Aging. 2014; 31 (10): 721–730.
  10. Thaler D.E., Ruthazer R., Weimar C., Mas J.L., Serena J., Di Angelantonio E., Papetti F., Homma S., Mattle H.P., Nedeltchev K., Mono M.L., Jaigobin C., Michel P., Elkind M.S., Di Tullio M.R., Lutz J.S., Griffith J., Kent D.M. Recurrent stroke predictors differ in medically treated patients with pathogenic vs. other PFOs. Neurology. 2014; 83 (3): 221–226.
  11. Abumiya T., Houkin K. Association of recurrent cerebral infarction with adenosine diphosphate and collagen induced platelet aggregation in patients treated with ticlopidine and/or aspirin. J. Stroke Cerebrovasc. Dis. 2011; 20 (4): 319–323.

Views

Abstract - 45

PDF (Russian) - 6

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies